158 related articles for article (PubMed ID: 35484029)
1. Multiple Sclerosis Progressive Courses: A Clinical Cohort Long-Term Disability Progression Study.
Cortesi PA; Fornari C; Capra R; Cozzolino P; Patti F; Mantovani LG
Value Health; 2022 Sep; 25(9):1489-1498. PubMed ID: 35484029
[TBL] [Abstract][Full Text] [Related]
2. The natural history of primary progressive multiple sclerosis: insights from the German NeuroTransData registry.
Braune S; Bluemich S; Bruns C; Dirks P; Hoffmann J; Heer Y; Rouzic EM; Bergmann A;
BMC Neurol; 2023 Jul; 23(1):258. PubMed ID: 37407914
[TBL] [Abstract][Full Text] [Related]
3. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
[TBL] [Abstract][Full Text] [Related]
5. Disability accrual in primary and secondary progressive multiple sclerosis.
Harding-Forrester S; Roos I; Nguyen AL; Malpas CB; Diouf I; Moradi N; Sharmin S; Izquierdo G; Eichau S; Patti F; Horakova D; Kubala Havrdova E; Prat A; Girard M; Duquette P; Grand'Maison F; Onofrj M; Lugaresi A; Grammond P; Ozakbas S; Amato MP; Gerlach O; Sola P; Ferraro D; Buzzard K; Skibina O; Lechner-Scott J; Alroughani R; Boz C; Van Pesch V; Cartechini E; Terzi M; Maimone D; Ramo-Tello C; Yamout B; Khoury SJ; La Spitaleri D; Sa MJ; Blanco Y; Granella F; Slee M; Butler E; Sidhom Y; Gouider R; Bergamaschi R; Karabudak R; Ampapa R; Sánchez-Menoyo JL; Prevost J; Castillo-Trivino T; McCombe PA; Macdonell R; Laureys G; Van Hijfte L; Oh J; Altintas A; de Gans K; Turkoglu R; van der Walt A; Butzkueven H; Vucic S; Barnett M; Cristiano E; Hodgkinson S; Iuliano G; Kappos L; Kuhle J; Shaygannejad V; Soysal A; Weinstock-Guttman B; Van Wijmeersch B; Kalincik T;
J Neurol Neurosurg Psychiatry; 2023 Sep; 94(9):707-717. PubMed ID: 37068931
[TBL] [Abstract][Full Text] [Related]
6. Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.
Boyko A; Therapontos C; Horakova D; Szilasiová J; Kalniņa J; Kolontareva J; Gross-Paju K; Selmaj K; Sereike I; Milo R; Gabelić T; Rot U
Mult Scler Relat Disord; 2021 May; 50():102778. PubMed ID: 33592384
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network.
Signori A; Lorscheider J; Vukusic S; Trojano M; Iaffaldano P; Hillert J; Hyde R; Pellegrini F; Magyari M; Koch-Henriksen N; Sørensen PS; Spelman T; van der Walt A; Horakova D; Havrdova E; Girard M; Eichau S; Grand'Maison F; Gerlach O; Terzi M; Ozakbas S; Skibina O; Van Pesch V; Sa MJ; Prevost J; Alroughani R; McCombe PA; Gouider R; Mrabet S; Castillo-Trivino T; Zhu C; de Gans K; Sánchez-Menoyo JL; Yamout B; Khoury S; Sormani MP; Kalincik T; Butzkueven H;
J Neurol Neurosurg Psychiatry; 2023 Jan; 94(1):23-30. PubMed ID: 36171104
[TBL] [Abstract][Full Text] [Related]
8. The natural history of early versus late disability accumulation in primary progressive MS.
Koch MW; Greenfield J; Javizian O; Deighton S; Wall W; Metz LM
J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):615-21. PubMed ID: 25091366
[TBL] [Abstract][Full Text] [Related]
9. Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.
Naegelin Y; Naegelin P; von Felten S; Lorscheider J; Sonder J; Uitdehaag BMJ; Scotti B; Zecca C; Gobbi C; Kappos L; Derfuss T
JAMA Neurol; 2019 Mar; 76(3):274-281. PubMed ID: 30615019
[TBL] [Abstract][Full Text] [Related]
10. The natural history of primary progressive multiple sclerosis.
Koch M; Kingwell E; Rieckmann P; Tremlett H
Neurology; 2009 Dec; 73(23):1996-2002. PubMed ID: 19996074
[TBL] [Abstract][Full Text] [Related]
11. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
[TBL] [Abstract][Full Text] [Related]
12. Modelling the natural history of primary progressive multiple sclerosis.
Harding KE; Wardle M; Moore P; Tomassini V; Pickersgill T; Ben-Shlomo Y; Robertson NP
J Neurol Neurosurg Psychiatry; 2015 Jan; 86(1):13-9. PubMed ID: 24828900
[TBL] [Abstract][Full Text] [Related]
13. Impact of multiple sclerosis relapses on progression diminishes with time.
Tremlett H; Yousefi M; Devonshire V; Rieckmann P; Zhao Y;
Neurology; 2009 Nov; 73(20):1616-23. PubMed ID: 19890070
[TBL] [Abstract][Full Text] [Related]
14. Clinical course of multiple sclerosis and labour-force absenteeism: a longitudinal population-based study.
Castelo-Branco A; Landfeldt E; Svedbom A; Löfroth E; Kavaliunas A; Hillert J
Eur J Neurol; 2019 Apr; 26(4):603-609. PubMed ID: 30414299
[TBL] [Abstract][Full Text] [Related]
15. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
16. Multiple sclerosis by phenotype in Germany.
Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
[TBL] [Abstract][Full Text] [Related]
17. Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
Leppert D; Kropshofer H; Häring DA; Dahlke F; Patil A; Meinert R; Tomic D; Kappos L; Kuhle J
Neurology; 2022 May; 98(21):e2120-e2131. PubMed ID: 35379762
[TBL] [Abstract][Full Text] [Related]
18. Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.
Signori A; Izquierdo G; Lugaresi A; Hupperts R; Grand'Maison F; Sola P; Horakova D; Havrdova E; Prat A; Girard M; Duquette P; Boz C; Grammond P; Terzi M; Singhal B; Alroughani R; Petersen T; Ramo C; Oreja-Guevara C; Spitaleri D; Shaygannejad V; Butzkueven H; Kalincik T; Jokubaitis V; Slee M; Fernandez Bolaños R; Sanchez-Menoyo JL; Pucci E; Granella F; Lechner-Scott J; Iuliano G; Hughes S; Bergamaschi R; Taylor B; Verheul F; Edite Rio M; Amato MP; Sajedi SA; Majdinasab N; Van Pesch V; Sormani MP; Trojano M
Mult Scler; 2018 Apr; 24(5):642-652. PubMed ID: 28382837
[TBL] [Abstract][Full Text] [Related]
19. Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities.
Tremlett H; Zhao Y; Devonshire V;
J Neurol; 2009 Mar; 256(3):374-81. PubMed ID: 19308306
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Health Utility in Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies.
Hernandez L; O'Donnell M; Postma M;
Pharmacoeconomics; 2021 Feb; 39(2):243-256. PubMed ID: 32989685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
